Class III β-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line
Open Access
- 21 June 2018
- journal article
- research article
- Published by Wiley in Analytical Cellular Pathology
- Vol. 2018, 1-11
Abstract
Eribulin is a new drug to treat soft tissue sarcoma (STS) that exerts antitumor activity by binding to microtubules. The prognosis of STS is poor, and eribulin is expected to improve the treatment outcome. We observed several cases that exhibited resistance to eribulin and developed an eribulin-resistant leiomyosarcoma cell line to investigate the mechanism of resistance. The IC50 of eribulin was 125 times higher in the resistant cell line than in the parental cell line, and eribulin did not induce G2/M arrest in resistant cells. The resistant cell line showed increased expression of MDR1 transcript, but protein levels and functional analysis results were similar to the parental cell line. We found that class III β-tubulin (TUBB3) was overexpressed in the resistant cell line, and siRNA knockdown of TUBB3 partially recovered sensitivity to eribulin. TUBB3 expression in clinical samples varied, suggesting that TUBB3 has the potential to be a biomarker for selection of anticancer drugs and may be a target for overcoming resistance to eribulin.Keywords
Funding Information
- Japan Society for the Promotion of Science (A 26713046, B 17k16696, 332)
- Japan Society for the Promotion of Science (A 26713046, B 17k16696, 332)
- Japan Orthopaedics and Traumatology Research Foundation Inc. (A 26713046, B 17k16696, 332)
This publication has 24 references indexed in Scilit:
- Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma†Japanese Journal of Clinical Oncology, 2016
- Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survivalOncoTargets and Therapy, 2016
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialThe Lancet, 2016
- Eribulin in Cancer TreatmentMarine Drugs, 2015
- Cadherin-11 regulates the metastasis of Ewing sarcoma cells to boneClinical & Experimental Metastasis, 2015
- Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting AgentClinical Cancer Research, 2015
- Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcomaBritish Journal of Cancer, 2013
- The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomasCancer, 2011
- Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing ConditionsCancer Research, 2011
- ATP‐binding cassette superfamily transporter gene expression in human soft tissue sarcomasInternational Journal of Cancer, 2004